S. Bauer

Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas.

F. Lordick, Ö. Türeci, U. Şahin, 2013 .

CLINICAL PRACTICE GUIDELINES Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up †

S. Sleijfer, E. Álava, E. Wardelmann, 2018 .

Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.

C. von Kalle, S. Fröhling, E. Schröck, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer.

K. Dhaene, Ö. Türeci, U. Şahin, 2018, European journal of cancer.

Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma

F. Janku, R. Ruiz-Soto, A. Spreafico, 2022, ESMO open.

Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.

W. Tap, P. Rutkowski, M. von Mehren, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

636PEFFICACY AND SAFETY OF MULTIPLE DOSES OF IMAB362 IN PATIENTS WITH ADVANCED GASTRO-ESOPHAGEAL CANCER: RESULTS OF A PHASE II STUDY.

Georg von Wichert, F. Lordick, Ö. Türeci, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

VOYAGER: An open-label, randomised, phase III study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST).

W. Tap, S. George, S. Bauer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B).

D. Ferry, S. Siena, J. Taieb, 2014 .